secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001193125-25-198777
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Chief Medical Officer Hetal Kocinsky departs; Andrew King to lead clinical programs
--------------------------------------------------------------------------------

- Hetal Kocinsky, M.D., left CMO role effective Sept 9, 2025.
- Company expects separation agreement: 12 months base salary plus 12 months COBRA premium payment.
- Dr. Andrew King, Ph.D, CSO & Head of R&D, will continue leading scientific and clinical programs.
- No successor named for CMO role; no details on search process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525198777/0001193125-25-198777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525198777/d116486d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-198777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer